drug_type
RELEVANT_DRUG
intervention_type
Biologic (bispecific T cell–engaging antibody)
drug_description
A subcutaneous bispecific T cell–engaging antibody that binds CD20 on malignant B cells and engages CD8/TCR on T cells, redirecting cytotoxic T cells to CD20+ targets to induce immune synapse formation, TCR signaling, cytokine release, and perforin/granzyme-mediated killing, leading to depletion of CD20+ B cells in CD20+ mature B-cell malignancies (LBCL, FL, MCL, CLL/SLL).
nci_thesaurus_concept_id
C210037
nci_thesaurus_preferred_term
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492
nci_thesaurus_definition
A trispecific immunoglobulin G (IgG)-like T-cell engaging (TCE) antibody targeting the tumor-associated antigen (TAA) CD20 and the T-cell surface antigens CD3 and CD8, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD20/anti-CD3/anti-CD8 trispecific antibody AZD5492 targets and binds to CD20 on CD20-expressing tumor B-cell, and the CD3 and CD8 antigens on CD8-positive T-lymphocytes. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor cells. CD20, a B-cell-specific cell surface antigen, is overexpressed in B-cell lineage malignancies.
drug_mesh_term
Antibodies, Bispecific
drug_category
TRISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
An IgG-like T cell–engaging antibody that binds CD20 on malignant B cells and CD3/CD8 on CD8+ T cells, crosslinking them to form an immune synapse, activating TCR signaling, cytokine release, and perforin/granzyme-mediated killing to deplete CD20+ B cells in B-cell malignancies.
drug_name
AZD5492
nct_id_drug_ref
NCT06542250